An observational study in HCC, Cirrhosis, Liver and NAFLD, sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2024-04-08.
Sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Liver Cirrhosis with a site in Italy — 22 open to participants now, 27 under way, 3 of them phase 3. Liver Cirrhosis · Italy.
Among the 78 studies in Liver Cirrhosis with a site in Italy, this one is the 27th largest by planned enrollment of the 31 observational ones that give a count, is one of 9 that started in 2023, is one of 31 observational ones, reaches primary completion later than 1 of the 26 other live ones, and was the 53rd registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →22 of the 78 studies in Liver Cirrhosis with a site in Italy are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Italy, Austria, Belgium and 9 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Boehringer Ingelheim · Sites in Italy, United States, Argentina and 34 more countries
Ages 18+
The Cleveland Clinic · Sites in Italy, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
European Foundation for Study of Chronic Liver Failure · Sites in Italy, France, Germany and 2 more countries
Ages 18–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 12 · Phase 4 4
First in 1998; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 105 across the 46 interventional studies, 320 across the 31 observational. Of the 40 that completed or were terminated, 10 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 78 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis is the lead sponsor of 55 studies on the registry; 19 are open to participants now.
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Liver Cirrhosis with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT06537466University of PalermoKetogenic Diet in MASLD-related cACLD | 2026-11 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07629128Fondazione Policlinico Universitario Agostino Gemelli IRCCSPatients With Primary Biliary Cholangitis(PBC) | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 78 studies in Liver Cirrhosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in high-risk subjects to develop this neoplasm.
In particular, it aims to:
HCC occurs in 70-95% of cases in patients with chronic liver disease, rarely in a "healthy" liver. Globally about 80% of HCCs are associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and their geographical distribution closely correlates with their epidemiology. Approximately 1/3 of patients with liver cirrhosis will develop HCC in the long term, with an annual risk ranging from 1%-8%.
Chronic viral hepatitis C (CHC) and chronic viral hepatitis B (CHB) together with cirrhosis of the liver respectively represent the most important risk factors in Western and Eastern Europe and therefore prolonged surveillance and prevention is recommended in these patients.
Therefore, early diagnosis of HCC is of paramount importance to prolong overall survival. Today, only about 30% of patients in Europe are diagnosed at an early stage, where curative treatments are possible.
Patients with a history of chronic liver disease are at risk of developing HCC and for this reason should undergo a screening program aimed at the early diagnosis of HCC. Asymptomatic patients but with familial predisposition on a genetic basis, according to recent international guidelines, they must be monitored periodically.
Imaging (ultrasonography, CT, and MRI), biopsy with histological examination, and blood alpha-fetoprotein measurements are used in diagnostics and staging. However, current screening/surveillance tools are not perfect.
The most popular screening tools for HCC are as follows and are performed on a semi-annual basis:
Tumor markers: Alpha-fetoprotein (α-FP) is a specific tumor marker. Its diagnostic sensitivity of HCC is 25-60% while its specificity is 76-96%. An α-FP level above 400 ng/mL is strongly diagnostic, but approximately two-thirds of patients with HCC \<4 cm has α-FP levels \<200 ng/mL and also approximately 20% of HCCs do not produce α-FP. The carbohydrate chain of α-FP is modified by fucosyltransferase during HCC development to give rise to lectin-bound α-FP (α-FP-L3) (sensitivity:40-90%; specificity:>90%) . The ratio of fucosylated α-FP to total α-FP is expressed as α-FP-L3%. Des-γ-carboxy-prothrombin (DCP or PIVKA-II) is an immature prothrombin, lacking carboxylation at various residues of glutamate (sensitivity: 48-62%; specificity: 81-98%). α-FP-L3 and DCP have been used routinely for 20 years in Japan. The combined use of these markers has increased the possibility of early detection of small HCCs. Prothrombin is formed after γ-carboxylation of vitamin K-dependent propeptides. DCP is produced due to an acquired post-translational defect in the carboxylase-vitamin K-dependent sequence of malignant cells.
Thus, DCP production is not increased in chronic hepatitis or cirrhosis, making it a potential marker to be used in the diagnosis of HCC. However, DCP measurement has no prognostic value in cases of vitamin K deficiency or inhibition of vitamin K function (for example in subjects on TAO with dicumarols) since its synthesis is also induced by the absence of vitamin K causing false values positive. For this reason DCP is also known as PIVKA-II (protein induced in vitamin K absence). Notwithstanding these limitations, many studies have demonstrated that PIVKA-II has a high sensitivity and specificity compared to α-FP in differentiating HCC from other chronic liver diseases. Liebman et al. demonstrated that PIVKA-II can be used not only as a very specific marker for HCC but also as a prognostic factor of HCC patients. The sensitivity, specificity, and odds ratio in HCC \<5 cm is 0.14-0.54, 0.95-0.99, and 6.86-29.7, respectively, with a cut-off of 40mAU /ml, and 0.07-0.56, 0.72-1 and 3.56-3 with a cut-off of 100mAU/ml. In a large study of 270 HCC patients who all had serum α-FP levels below 20 ng/mL, the combined use of the biomarkers α-FP-L3 and DCP detected 49% of all HCC patients of size less than 2cm. Furthermore, α-FP-L3 measurements with the highly sensitive method before treatment were more useful for the diagnosis and prognosis of HCC than with the conventional method. More recently, the three markers (α-FP, α-FP-L3 and DCP) showed a sensitivity and specificity of 85% (n=304 HCC patients versus 403 controls) in the early diagnosis of HCC in a German cohort.
"Biomarkers of HCC and their clinical significance"
Ideally, the use of serum biomarkers with adequate sensitivity and specificity could allow early diagnosis of HCC by avoiding surveillance with ultrasonography. A number of serum biomarkers, other than α-fetoprotein (α-FP) have been included in some score systems for the prediction of HCC.
However, at present, none of the biomarkers have been validated in phase III clinical trials and are used in clinical practice, except for α-FP and DCP (or PIVKAII), which are recommended by the Japanese HCC guidelines. This can be explained by the high heterogeneity of HCC biology, where alterations of different biochemical pathways are involved in the tumourigenesis process. Indeed, patients with HCC show various patterns of positivity for biomarkers of HCC.
CLINICAL STUDY DESIGN As previously indicated, this is a retrospective and prospective observational study in which the biomarkers useful for evaluating the possible progression of chronic liver disease in HCC will be dosed in two groups, a "Case" group and a "Control" group.
The need to identify biomarkers useful for predicting the possible onset of HCC in patients with chronic liver disease arises from the fact that:
The following will be enrolled in the study, after signing the informed consent:
The study will last for two years, and it is expected to enroll at least 30 patients for each group.
Upon enrollment and after 6 months, at follow-up, the patients belonging to both groups will have a blood sample taken to proceed with the dosage of the biomarkers.
The control group will be composed of patients who will be candidates for HCC surveillance, i.e. those with liver cirrhosis or chronic hepatitis of any aetiology without HCC seen at our institution.
Included in this group are:
Control patients will be required to undergo a 6-month follow-up following GALAD score evaluation to confirm the absence of HCC. These patients should have a negative multiphasic contrast-enhanced CT, MRI, or liver biopsy at the time of GALAD score evaluation.
The case group will be composed of patients with newly diagnosed HCC in the context of cirrhosis or any other aetiology during the same study period. This group will include:
Any patients undergoing therapy with Warfarin, an anticoagulant, will be excluded since it can increase DCP levels in the absence of HCC, risking giving false positives.
Considering that the study foresees a follow-up of at least 6 months of the recruited subjects and therefore rather long times are envisaged for its completion, it is conceivable that some patients will be lost and that the initial population will decrease. For this reason, recruitment will proceed throughout the study.
To participate in this study, patients belonging to the Gastroenterology 1 department of the IRCCS "Saverio de Bellis" will be enrolled.
The control group will be composed of patients who will be candidates for HCC surveillance, i.e. those with liver cirrhosis or chronic hepatitis of any aetiology without HCC seen at our institution.
The case group will be composed of patients with newly diagnosed HCC in the context of cirrhosis or any other aetiology during the same study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Case Group:
Controls group:
Exclusion Criteria:
The control group will be composed of patients who will be candidates for HCC surveillance, i.e. those with liver cirrhosis or chronic hepatitis of any aetiology without HCC seen at our institution. Included in this group are: 1. Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up; 2. Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP.
Diagnostic Test: Biomarker dosage
The case group will be composed of patients with newly diagnosed HCC in the context of cirrhosis or any other aetiology during the same study period. This group will include: 1. Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up; 2. Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP at the time of tumor diagnosis.
Diagnostic Test: Biomarker dosage
The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
Biomarker dosage
Determine the GALAD alghoritm (Gender,Age, AFP-L3, AFP and Des-carboxy-prothrombin) by evaluating the values of AFP, AFP-L3, Des-carboxy-prothrombin for each patient, since the GALAD score had a high diagnostic performance as compared to each standalone markers in identifying HCC at any stage.
Time frame: six months
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Jun 2024, 16 months after the start.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 16 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis